Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pieris Pharma (PIRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,771
  • Shares Outstanding, K 44,790
  • Annual Sales, $ 5,830 K
  • Annual Income, $ -22,800 K
  • 36-Month Beta 1.68
  • Price/Sales 44.40
  • Price/Cash Flow 0.00
  • Price/Book 56.29

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.58 +32.97%
on 10/26/17
6.25 -2.56%
on 11/17/17
+0.81 (+15.34%)
since 10/17/17
3-Month
4.58 +32.97%
on 10/26/17
6.58 -7.45%
on 10/06/17
+1.46 (+31.53%)
since 08/17/17
52-Week
1.34 +354.48%
on 12/15/16
6.58 -7.45%
on 10/06/17
+4.49 (+280.63%)
since 11/17/16

Most Recent Stories

More News
Pieris Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 10:00 AM...

PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update

BOSTON, MA--(Marketwired - November 08, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update

BOSTON, MA--(Marketwired - November 08, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 6.09 (+5.36%)
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business....

INO : 4.72 (+1.72%)
PFE : 35.37 (-0.53%)
MKGAF : 107.5000 (+1.19%)
PIRS : 6.09 (+5.36%)
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

PBYI : 105.50 (+2.28%)
RGNX : 27.55 (-1.96%)
INO : 4.72 (+1.72%)
PIRS : 6.09 (+5.36%)
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

BDSI : 2.25 (unch)
RGNX : 27.55 (-1.96%)
INO : 4.72 (+1.72%)
PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017

BOSTON, MA--(Marketwired - November 02, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017

BOSTON, MA--(Marketwired - November 02, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals to Present at Investor Conferences in November

BOSTON, MA--(Marketwired - November 01, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

PIRS : 6.09 (+5.36%)
Pieris Pharmaceuticals to Present at Investor Conferences in November

BOSTON, MA--(Marketwired - November 01, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

PIRS : 6.09 (+5.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Key Turning Points

2nd Resistance Point 6.54
1st Resistance Point 6.31
Last Price 6.09
1st Support Level 5.80
2nd Support Level 5.52

See More

52-Week High 6.58
Last Price 6.09
Fibonacci 61.8% 4.58
Fibonacci 50% 3.96
Fibonacci 38.2% 3.34
52-Week Low 1.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart